Skip to Main Content

Quantgene

  • sam patrick posted an article
    Vikor Scientific and Quantgene announce major advance in precision genomics see more

    Courtesy of GSA Business

    Starting this March, a South Carolina lab will become ground zero for a preventative test that can detect cancer-causing mutations, risks or tumors in advance through a quick blood sample taken at home or a physician’s office.

    S.C. life science organization SCBio and the Charleston Regional Development Alliance linked together Charleston’s Vikor Scientific and California’s Quantgene Inc. when the West Coast company was on the hunt for a lab that could commercialize its AI and genomic-powered preventative care program, Serenity.

    Serenity puts to task a deep genomic sequence process that covers 20,000 genes in combination with the disease, medication and lifestyle risks that could contribute to multiple variations of cancer. Along with the blood test, or “liquid biopsy,” it can detect cancerous mutations in the blood, according to Vikor Scientific co-founder Shea Harrelson.

    “What this means is that we can detect cancer early enough so that patients don’t have to resort to chemotherapy,” she said during SCBio’s Virtual Meeting Wednesday morning. “They may have options for immunotherapy or aggressive preventative strategies or even excisional therapy.”

    Patient-specific health profiles covering personal and family history, as well as lifestyle choices, will brief analysts on how additional risks may contribute to a patient’s likelihood of developing early-stage cancer, thus prompting preventative care.

    “With Serenity, we are first-to-market in combining liquid biopsy cancer detection with whole exome sequencing and advanced medical intelligence,” Johannes Bhakdi, founder and CEO of Quantgene, said in a news release. “We hope to unlock a new era in medicine in which trained physicians can detect multiple cancers at early stages in the blood with single molecule precision. Serenity brings genomic technologies to patients within an innovative system of preventative care that we believe will set a new standard in patient-centered personalized medicine. We are excited to take this important step with our partners at Vikor Scientific.”

    Vikor Scientific, a hub for medical testing, will process test results in collaboration with Serenity’s proprietary cloud for both individual end-users and health care professionals.

    The South Carolina company will launch its public awareness and physician education campaigns alongside the concierge-product release on March 1, according to Scotty Branch, co-founder of Vikor Scientific, and will soon build out its current location in Charleston.

    “Our number one goal is to educate physicians throughout the country, which is what we do best,” Branch told GSA Business Report, adding that the team is working to get insurance companies on board with the treatment program now.

    “Until then, the liquid biopsy, or the early detection portion, will be on a concierge or cash-paid basis,” he said.

    Vikor Scientific will conduct whole exome sequencing and send that information to the Serenity cloud for both physicians and individual consumers, potentially for a variety of uses.

    While existing genetic tests on the market like those sold by 23 and Me may be able to offer a surface level detection of certain cancer-causing genetic variations in a patient, Serenity takes genomic testing to the next step of preventative treatment, the company said.

    “Genetic mutations only play a role in about 5% to 10% of cancer,” Harrelson said. “So, there’s about 90-95% of cancers that don’t have genetic mutations, and without that, you still have a lot of familial cancers. And most people die from cancer than heart disease or automobile accidents, so this liquid biopsy test will be very important, because if patients have put stress on their body or smoke or other risk factors that can increase their chance for cancer, this liquid biopsy test is pretty painless and a great screening tool for this and other cancers that … like pancreatic cancer. We often don’t find out about pancreatic cancer until stage three or four.”

    Taking into account detected at-risk genetic variations, the Vikor-Quantgene team will analyze additional risks for early stages of cancer through the liquid biopsy test, in lieu of more invasive measures, which can detect whether nascent tumors are forming in the body.

    “It’s a great continuum of care,” he added. The test analysis could then be used, in tandem with additional data, to launch preventative treatment and care.

    “We need to use liquid biopsy as part of an annual or bi-annual screening,” Branch said.

    After a Monday Vikor Scientific Board meeting, Branch said 99% of the plans for the facility buildout have been nailed down. The full announcement will come when the company approves the final portion of its development strategy.

    “This is an amazing announcement for South Carolina and for economic development, where we are going to build out at our location at 22 West Edge, where Vikor’s location is currently,” he said. The company will start small with 10 to 20 new employees and scale up from there. “That is exciting news that a corporate hub would be located here in Charleston’s West Edge Medical Innovation District."

  • sam patrick posted an article
    Founders take virtual stage at South Carolina life sciences conference to introduce technology see more

    Founders take virtual stage at South Carolina life sciences conference to introduce revolutionary ability for early detection of cancer mutations

     

    Santa Monica, CA and Charleston, SC -- Feb. 17, 2021Vikor Scientific, a South Carolina-based leading, molecular diagnostics company with a rapidly expanding nationwide footprint, has announced a strategic investment in California-based Quantgene Inc. to accelerate the commercialization of Quantgene’s flagship product, SerenityTM. Serenity provides world-leading accuracy in precision genomics and AI-enabled personalized preventative care.

    Quantgene’s Serenity combines advanced next-generation sequencing with proprietary cloud and AI technology to uncover deeper and more meaningful health insights earlier. Serenity will launch with four core components of health protection:

    • Liquid biopsy to detect cancer-related mutations in the blood to support early detection
    • Deep genomic sequencing across all 20,000 genes for a more complete picture of disease, medication and lifestyle risks
    • In-depth patient health profiles including health history, family history and lifestyle to bring more context to test results
    • An expert clinical team to provide analysis and connect patients to a network of world-leading medical experts

     

    The combination of these components allow the system to detect, flag and monitor disease and disease risk at earlier stages. Early intervention for potentially fatal conditions like cancer is critical to ensuring better treatment response and long-term outcomes. This is a critical advancement in marrying medicine and technology to ensure the company realizes their mission of extending the average lifespan of members by a decade within a decade.

    South Carolina-based Vikor Scientific is a market leader in providing targeted, molecular diagnostics that can improve clinical and economic outcomes.  Headquartered in Charleston, S.C., Vikor anchors the WestEdge Life Sciences Campus adjacent to the Medical University of South Carolina and is approaching 400 employees nationwide.  The announcement was made at SCBIO 2021, the acclaimed national conference of South Carolina’s life sciences industry which draws industry leaders from around the globe.

    In addition to ensuring the successful launch of Serenity commercially, the new partners have plans to launch several downstream liquid biopsy-based clinical oncology products including minimum residual disease detection (“MRD”), recurrence monitoring and companion diagnostics over the next several months. Vikor Scientific will leverage their proven commercialization engine for innovative molecular diagnostics technologies and leverage their growing national salesforce in service of the new product roll outs.

    Shea Harrelson, co-founder of Vikor Scientific, said: “In Quantgene, Vikor saw a compelling opportunity to support the commercialization of advanced genomics in the service of preventative care and positively impacting the course of many chronic diseases, starting with cancer. This partnership aligns perfectly with our mission as a company - to improve patient outcomes and prevent unnecessary healthcare costs and delays in treatment by improving diagnostic accuracy, reducing turnaround time and personalizing treatment options.”

    Scotty Branch, co-founder of Vikor Scientific added: “Changing the paradigm of healthcare has always been the vision for Vikor Scientific. The platform built by the Quantgene team is revolutionary and certain to accelerate the speed at which we diagnose and treat patients for cancer. Vikor is excited to lead the commercialization and expand on our mission of driving clinical outcomes. And we are particularly excited to do so here in Charleston, where we envision a dynamic future for innovation, growth and expansion of the booming life sciences hub here in South Carolina.”

    “With Serenity, we are first-to-market in combining liquid biopsy cancer detection with whole exome sequencing and advanced medical intelligence. We hope to unlock a new era in medicine in which trained physicians can detect multiple cancers at early stages in the blood with single molecule precision.” added Jo Bhakdi, founder and CEO of Quantgene. “Serenity brings genomic technologies to patients within an innovative system of preventative care that we believe will set a new standard in patient-centered personalized medicine. We are excited to take this important step with our partners at Vikor Scientific.”

    Alluding to Serenity as a new frontier in science that “promises earlier detection than ever and promises to unlock a new era of medicine,” Branch saluted the role of SCBIO and the Charleston Regional Development Authority in making the announcement a reality.

    “I can envision the day when this collaboration leads to a new corporate hub here with new labs and bright new talent from South Carolina medical schools advancing this revolutionary technology,” Branch added.  “We credit the efforts of SCBIO and this state in bringing our organization and Quantgene together, and we intend to identify new collaborations and partnerships that advance the future of medicine, and promise a healthier future for our state, country and world.”